Keiichi Nakagawa
Papers
2
Total Citations
10
H-Index
2
About
Dr. Keiichi Nakagawa is a leading figure in the comparative effectiveness of frontline therapies for localized prostate cancer, with a focused expertise in urologic oncology and radiation oncology. His major contributions lie in directly comparing the long-term outcomes of robot-assisted radical prostatectomy (RARP) against volumetric modulated arc therapy (VMAT), a sophisticated form of intensity-modulated radiotherapy. In his landmark 2019 study, Dr. Nakagawa provided one of the first direct comparisons of these two advanced techniques, a critical analysis that has garnered 7 citations. He further solidified this work with a 2024 propensity score-matched analysis, extending the follow-up to six years to evaluate mortality outcomes—a dimension previously lacking in the literature. This latter study, with 3 citations, addresses a crucial gap by assessing not just functional or biochemical outcomes, but survival. By systematically comparing the leading surgical and radiotherapeutic approaches, Dr. Nakagawa’s research offers vital, evidence-based guidance for clinicians and patients navigating treatment decisions for localized prostate cancer, directly influencing clinical practice in this high-stakes field.
Research Focus
Key Achievements
Top Papers
- 1
- 2